

Zydus receives final approval from the USFDA for Carbidopa Tablets

Ahmedabad, 10 May, 2018

Zydus Cadila has received the final approval from the USFDA to market Carbidopa Tablets, 25 mg. It is used with a combination levodopa/carbidopa product to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
